Climb Bio, Inc.
NASDAQ:CLYMBiotechnology
+$0.02 today
- Market cap
- $574.46M
- Beta
- 0.10
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.77
Volume 0.59M
Average 0.88M
Returns on capital
Climb Bio, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-37.3%
avg -42.3%
ROIC
-42.2%
avg -43.9%
ROA
-35.7%
avg -39.6%
Analysis
ROA is currently the strongest return metric at -35.7% versus its period average of -39.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Aoife Brennan BCh MMSc | Chief Executive Officer, President & Director | USD 1.09M | 50 | — | — |
Perrin Wilson | Chief Business Officer | USD 793.42K | 47 | — | — |
Susan Altschuller | CFO & Principal Accounting Officer | USD 570.81K | 44 | 142.50K | 0.21% |
Edgar D. Charles | Chief Medical Officer | — | — | — | — |
Adam Villa | Senior Vice President of Technical Operations | — | — | — | — |
Chandra Adams | Senior VP, General Counsel & Secretary | — | — | — | — |
Ashley Jones | Senior Vice President of People & Workforce Strategy | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 6, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$779,625.64
Sells
6
$2.65M
Net Transaction Value
−$1.87M
Net selling
Most Active
Thomas Stephen Basil
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 15, 26Sep 15, 2026 | Thomas Stephen Basil Direct | Sell | $1.4M$1,366,820.00 |
| Jun 29, 26Jun 29, 2026 | Brennan Aoife Direct | Sell | $407K$406,979.34 |
| Feb 26, 26Feb 26, 2026 | Thomas Stephen Basil Direct | Sell | $114.3K$114,288.88 |
| Feb 25, 26Feb 25, 2026 | Thomas Stephen Basil Direct | Sell | $236K$235,963.96 |
| Feb 13, 26Feb 13, 2026 | Thomas Stephen Basil Direct | Sell | $58.1K$58,141.00 |
| Feb 12, 26Feb 12, 2026 | Thomas Stephen Basil Direct | Sell | $471K$470,988.00 |
| Jan 5, 26Jan 5, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Buy | $24.9K$24,888.50 |
| Dec 12, 25Dec 12, 2025 | RA CAPITAL MANAGEMENT, L.P. Indirect | Buy | $290.2K$290,181.32 |
| Dec 11, 25Dec 11, 2025 | RA CAPITAL MANAGEMENT, L.P. Indirect | Buy | $464.6K$464,555.82 |
Summary
Insiders reported 3 buys worth $779,625.64 and 6 sells worth $2.65M over the last 12 months. That adds up to net selling of $1.87M. Thomas Stephen Basil was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Climb Bio, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about CLYM's management, answered from reported figures.
Who manages CLYM?
Climb Bio, Inc. (CLYM) lists 7 active executives. The top listed executive is Aoife Brennan BCh MMSc, Chief Executive Officer, President & Director.
Are CLYM insiders buying or selling?
Recent insider activity shows net buying of $13.21M.
Continue the stock analysis
Jump to another research area for this company.